Wells Pharma OF Houston LLC: FDA regulatory profile

Wells Pharma OF Houston LLC appears in 7 indexed U.S. FDA records: 7 recall records, naming 7 distinct products. Latest dated event: a recall record dated 2026-05-06. Observations run 2026-05-06 to 2026-05-06, 7 dated records across 1 calendar year, busiest 2026 with 7. Recalls: 7 Class II (100%); 7 ongoing by lifecycle status, reported 2026-05-06; 7 with an FDA recall number, 7 with an initiation date, across 1 state, grouped into 1 FDA recall event. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. Recall records: Phenylephrine Hydrochloride Injectable Solution (D-0502-2026, Class II, 2026-05-06), fentaNYL Citrate Injectable Solution (D-0503-2026, Class II, 2026-05-06), fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride (D-0504-2026, Class II, 2026-05-06) and fentaNYL Citrate Injectable Solution (D-0505-2026, Class II, 2026-05-06). Recalling-firm addresses are recorded in TX. Its recall lines are grouped by the FDA into 1 event identifier: 98694.

Regulatory snapshot

Indexed records 7
Recall records 7
Shortage entries 0
Source rows filed 0
Approval records 0
Current shortages 0
Resolved shortages 0
Discontinued shortages 0
Unique products 7
Recall classifications Class II: 7
Recall statuses Ongoing: 7
First observed 2026-05-06
Latest observed 2026-05-06
Latest event type recall
Dated observations 7
Years covered 1
Span (days) 0
Busiest year 2026 (7 records)
Recall states 1
With recall number 7 of 7
FDA recall events 1
Related firms / shortages 0 / 0

Counts, not a rating. Coverage-limited activity signals over the ingested window — never reputational scores or judgements about the firm or its products.

Record breakdown

DimensionValueRecordsShare
Recall classificationClass II7100%
Recall statusOngoing7100%

Recall history (7)

Every enforcement report attributed to this firm, newest first. Classification is the FDA's severity tier, status its lifecycle position — neither is a safety statement.

Product (as published)Recall numberClassificationStatusReportedInitiated
Phenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma of Houston D-0502-2026 Class II Ongoing 2026-05-06 2026-04-01
fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 D-0503-2026 Class II Ongoing 2026-05-06 2026-04-01
fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mcg/ 250 mL) D-0504-2026 Class II Ongoing 2026-05-06 2026-04-01
fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, D-0505-2026 Class II Ongoing 2026-05-06 2026-04-01
fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL D-0506-2026 Class II Ongoing 2026-05-06 2026-04-01
Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kit D-0507-2026 Class II Ongoing 2026-05-06 2026-04-01
fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), D-0508-2026 Class II Ongoing 2026-05-06 2026-04-01

Browse the wider classification index: Class II recalls.

Products and drugs named (7)

De-duplicated by record entity, not raw source row.

Source limitations

Built from the 7 ingested FDA records for this firm (7 recall, 0 shortage, 0 approval) — not its full regulatory history. The window is finite and can lag the live record, and alternate spellings of a firm name may sit under separate profiles. Confirm details at the linked official source. Regulatory information only: no safety assessment, no recommendation.

Where to go next

Source & provenance

Official source
https://open.fda.gov/apis/drug/enforcement/
Source dataset
openFDA (enforcement + shortages + Drugs@FDA)
Publication date
Not available
Ingested
2026-08-22

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.